CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.

ABSTRACT:

Background

Acute Myeloid leukemia is a heterogeneous disease that requires novel targeted treatment options tailored to the patients' specific microenvironment and blast phenotype.

Methods

We characterized bone marrow and/or blood samples of 37 AML patients and healthy donors by high dimensional flow cytometry and RNA sequencing using computational analysis. In addition, we performed ex vivo ADCC assays using allogeneic NK cells isolated from healthy donors and AML patient material to test the cytotoxic potential of CD25 Mab (also referred to as RG6292 and RO7296682) or isotype control antibody on regulatory T cells and CD25+ AML cells.

Results

Bone marrow composition, in particular the abundance of regulatory T cells and CD25 expressing AML cells, correlated strongly

SUBMITTER: Pousse L 

PROVIDER: S-EPMC10185852 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature